These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27721339)

  • 1. Investigation of Formulation and Process of Lyophilised Orally Disintegrating Tablet (ODT) Using Novel Amino Acid Combination.
    AlHusban F; ElShaer AM; Kansara JH; Smith AM; Grover LM; Perrie Y; Mohammed AR
    Pharmaceutics; 2010 Jan; 2(1):1-17. PubMed ID: 27721339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Texture Analysis Technique in Formulation Development of Lyophilized Orally Disintegrating Tablets Containing Mannitol, Polyvinylpyrrolidone and Amino Acids.
    Hackl E; Ermolina I
    AAPS PharmSciTech; 2019 Jan; 20(2):71. PubMed ID: 30631978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
    Sotoyama M; Uchida S; Kamiya C; Tanaka S; Kashiwagura Y; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
    Chem Pharm Bull (Tokyo); 2019; 67(6):540-545. PubMed ID: 31155559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New advances in the characterization of lyophilised orally disintegrating tablets.
    Vanbillemont B; Everaert H; De Beer T
    Int J Pharm; 2020 Apr; 579():119153. PubMed ID: 32084575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
    Al-Khattawi A; Mohammed AR
    Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents.
    AlHusban F; Perrie Y; Mohammed AR
    Eur J Pharm Biopharm; 2010 Jun; 75(2):254-62. PubMed ID: 20332027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets.
    Song H; Moon C; Lee BJ; Oh E
    J Pharm Sci; 2018 Jul; 107(7):1886-1895. PubMed ID: 29530714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Formulation Advances and Therapeutic Usefulness of Orally Disintegrating Tablets (ODTs).
    Chinwala M
    Pharmacy (Basel); 2020 Oct; 8(4):. PubMed ID: 33050437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use.
    Comoglu T; Dilek Ozyilmaz E
    Pharm Dev Technol; 2019 Sep; 24(7):902-914. PubMed ID: 31215850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook.
    Elwerfalli AM; Ghanchi Z; Rashid F; Alany RG; ElShaer A
    Curr Drug Deliv; 2015; 12(6):652-67. PubMed ID: 25760951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized furosemide taste masked orally disintegrating tablets.
    Ibrahim MA; Abou El Ela AESF
    Saudi Pharm J; 2017 Nov; 25(7):1055-1062. PubMed ID: 29158715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets.
    Shoukri RA; Ahmed IS; Shamma RN
    Eur J Pharm Biopharm; 2009 Sep; 73(1):162-71. PubMed ID: 19406232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conceptualisation, Development, Fabrication and In Vivo Validation of a Novel Disintegration Tester for Orally Disintegrating Tablets.
    Koner JS; Rajabi-Siahboomi AR; Missaghi S; Kirby D; Perrie Y; Ahmed J; Mohammed AR
    Sci Rep; 2019 Aug; 9(1):12467. PubMed ID: 31462654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
    Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
    Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
    Cantor SL; Khan MA; Gupta A
    Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new modified wetting test and an alternative disintegration test for orally disintegrating tablets.
    Hooper P; Lasher J; Alexander KS; Baki G
    J Pharm Biomed Anal; 2016 Feb; 120():391-6. PubMed ID: 26774944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions.
    Dehghani H; Taheri A; Homayouni A
    Curr Drug Deliv; 2017; 14(5):709-717. PubMed ID: 27142108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets.
    Wagner-Hattler L; Wyss K; Schoelkopf J; Huwyler J; Puchkov M
    Int J Pharm; 2017 Dec; 534(1-2):50-59. PubMed ID: 28987455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
    Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of multiparticulate systems as lyophilised orally disintegrating tablets.
    Alhusban F; Perrie Y; Mohammed AR
    Eur J Pharm Biopharm; 2011 Nov; 79(3):627-34. PubMed ID: 21693189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.